Literature DB >> 16818620

Suppression of lung tumor formation by the regulatory subunit of ribonucleotide reductase.

Ashish Gautam1, Gerold Bepler.   

Abstract

The nucleotide metabolism enzyme ribonucleotide reductase is composed of a regulatory subunit (RRM1) and a catalytic subunit (RRM2). The RRM1 locus has frequent loss of heterozygosity in lung cancers, ectopic expression of RRM1 suppresses proliferation of ras-transformed mouse fibroblasts, and high levels of RRM1 expression are associated with a significant survival benefit in patients with lung cancer. In RRM1 transgenic human lung and colon cancer cell lines, we observed induction of G(2) cell cycle arrest, apoptosis, and efficient DNA damage repair. We generated strains of RRM1 transgenic mice and found that carcinogen-induced lung tumor formation was significantly suppressed. The tumor suppression was more pronounced in strains with high levels of RRM1 expression than in those with low levels of expression. DNA damage repair capacity in transgenic animals was determined, and RRM1 transgenic animals repaired chemically induced DNA damage with greater efficiency than control animals. We conclude that the regulatory subunit of ribonucleotide reductase has tumor suppressor activity that is mediated through efficient DNA damage repair.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16818620     DOI: 10.1158/0008-5472.CAN-05-4462

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  38 in total

1.  Ribonucleotide reductase subunit M1 expression in resectable, muscle-invasive urothelial cancer correlates with survival in younger patients.

Authors:  Lauren C Harshman; Gerold Bepler; Zhong Zheng; John P Higgins; Genevera I Allen; Sandy Srinivas
Journal:  BJU Int       Date:  2010-12       Impact factor: 5.588

2.  RRM1 and RRM2 pharmacogenetics: association with phenotypes in HapMap cell lines and acute myeloid leukemia patients.

Authors:  Xueyuan Cao; Amit K Mitra; Stanley Pounds; Kristine R Crews; Varsha Gandhi; William Plunkett; M Eileen Dolan; Christine Hartford; Susana Raimondi; Dario Campana; James Downing; Jeffrey E Rubnitz; Raul C Ribeiro; Jatinder K Lamba
Journal:  Pharmacogenomics       Date:  2013-09       Impact factor: 2.533

3.  A change of strategy in the war on cancer.

Authors:  Robert A Gatenby
Journal:  Nature       Date:  2009-05-28       Impact factor: 49.962

Review 4.  Metabolic genes in cancer: their roles in tumor progression and clinical implications.

Authors:  Eiji Furuta; Hiroshi Okuda; Aya Kobayashi; Kounosuke Watabe
Journal:  Biochim Biophys Acta       Date:  2010-02-01

5.  Nuclear RNR-α antagonizes cell proliferation by directly inhibiting ZRANB3.

Authors:  Yuan Fu; Marcus J C Long; Somsinee Wisitpitthaya; Huma Inayat; Timothy M Pierpont; Islam M Elsaid; Jordana C Bloom; Joaquin Ortega; Robert S Weiss; Yimon Aye
Journal:  Nat Chem Biol       Date:  2018-08-27       Impact factor: 15.040

6.  Non-enzymatic action of RRM1 protein upregulates PTEN leading to inhibition of colorectal cancer metastasis.

Authors:  Hongyan Qi; Meng Lou; Yuexia Chen; Xiyong Liu; Naiming Chen; Jianzhen Shan; Zhiqiang Ling; Jing Shen; Lijun Zhu; Yun Yen; Shu Zheng; Jimin Shao
Journal:  Tumour Biol       Date:  2015-02-01

7.  A phase II trial of triapine (NSC# 663249) and gemcitabine as second line treatment of advanced non-small cell lung cancer: Eastern Cooperative Oncology Group Study 1503.

Authors:  Anne M Traynor; Ju-Whei Lee; Gerald K Bayer; John M Tate; Sachdev P Thomas; Miroslaw Mazurczak; David L Graham; Jill M Kolesar; Joan H Schiller
Journal:  Invest New Drugs       Date:  2009-02-24       Impact factor: 3.850

8.  Microenvironmental Influences on Metastasis Suppressor Expression and Function during a Metastatic Cell's Journey.

Authors:  Wen Liu; Carolyn J Vivian; Amanda E Brinker; Kelsey R Hampton; Evi Lianidou; Danny R Welch
Journal:  Cancer Microenviron       Date:  2014-06-18

9.  A theoretical quantitative model for evolution of cancer chemotherapy resistance.

Authors:  Ariosto S Silva; Robert A Gatenby
Journal:  Biol Direct       Date:  2010-04-20       Impact factor: 4.540

10.  Modulation of the ribonucleotide reductase-antimetabolite drug interaction in cancer cell lines.

Authors:  Jun Zhou; Paula Oliveira; Xueli Li; Zhengming Chen; Gerold Bepler
Journal:  J Nucleic Acids       Date:  2010-09-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.